III. International Symposium on Peritoneal DialysisMorphology, Physiology, Kinetics, Drugs.- The Ultrastructure of the Parietal Peritoneum in Normal and Uremic Man and in Patients on CAPD.- The Morphology of the Peritoneum in CAPD Patients.- Fenestrated Capillaries in the Human Parietal Peritoneum and Rabbit Diaphragmatic Peritoneum.- Lymph Flow from the Peritoneal Cavity in CAPD Patients.- A Distributed Model of Peritoneal Transport.- Maximal Peritoneal Pore Size Determined by Dextran Transport.- Peritoneal Absorption of Macromolecules.- Peritoneal Membrane Permeability for High and Low Molecular Weight Proteins (H/LMWP) in CAPD.- Follow-up of Peritoneal Mass Transfer Properties in Long-term CAPD Patients.- Dependence of Middle Molecular Clearance on Protein Concentration of Peritoneal Fluid.- An International Survey of Ultrafiltration in CAPD.- Changes in Ultrafiltration and Solute Transport During CAPD.- Prediction of Changes in Transperitoneal Water Transport During CAPDA Prospective Study.- Influence of Blood Flow and Plasma Proteins on UF Rate in Peritoneal Dialysis.- Prognostic Value of Peritoneal Equilibration Curves in CAPD Patients.- Role of Peritoneal Membrane Hydration in UF Capacity of Patients on CAPD.- Studies on Peritoneal UF Loss: The UF Coefficient (K) as an Index of the PM Filtration Efficiency.- Increased Peritoneal Ultrafiltration Due to Amphotericin B Augmented Sodium Transport.- Serum Concentration and Peritoneal Transfer of Aluminum during Treatment by CAPD.- Calcium Peritoneal Mass Transfer in CAPD.- Changes in Plasma Protein Spectra after IP Injection of Hypertonic and Isotonic Solutions.- Pharmacokinetics of Cefotaxime during CAPD.- Multiple Dose IP Vancomycin Kinetics during CAPD.- IP Administration of Moxalactam during CAPD.- Technology Access, Solutions.- Experimental and Clinical Origins of Peritoneal Dialysis for Renal Failure.- The Sorbent Suspension Reciprocating Dialyzer for Use in Peritoneal Dialysis.- Application of Antibiotic Bl'